angustia j, woggon b, schoepf j. the treatment of depression with l-5-hydroxytryptophan versus imipramine. results of two open studies and one double-blind study. arc psychiatrist nervenkr. 1977;224(2):175-186.
attele as, xie jt, yuan cs. treatment of insomnia: an alternative approach. alternate med rev. 2000;5(3):249-259.
salt for birds tc. 5-hydroxytryptophan: a clinically effective serotonin precursor. alternate med rev. 1998;3(4):271-280.
byerley wf, judd ll, reimherr fw, grosser bi. 5-hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. psychopharmaceutical j clin. 1987;7(3):127-137.
cangiano c, laviano a, del ben m, et al. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients. int j obes relat metab disord. 1998;22(7):648-654.
cangiano c, ceci f, cascino a, et al. Eating behavior and compliance with dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. j clin nutr. 1992;56(5):863-867.
caruso i, sarzi puttini p, cazzola m, azzolini v. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. j int med res. 1990;18(3):201-209.
cauffield js, forbes hj. dietary supplements used in the treatment of depression, anxiety, and sleep disorders. lippincotts prim care pract. 1999;3(3):290-304.
ceci f, cangiano c, cairella m, et al. the effects of oral administration of 5-hydroxytryptophan on eating behavior in obese adult women. neural transmission j. 1989;76(2):109-117.
jj curcio, ls kim, d wollner, ba pockaj. The potential of 5-hydroxytryptophan for the reduction of hot flashes: a hypothesis. alternate med rev. 2005;10(3):216-221.
debenedittis g, massei r. Serotonin precursors in chronic primary headache. a double-blind crossover study with l-5-hydroxytryptophan versus placebo. j neurosurgery sci. 1985;29(3):239-248.
elko cj, burgess jl, robertson wo. Zolpidem-associated hallucinations and serotonin reuptake inhibition: a possible interaction. j toxicol clin toxicol. 1998;36(3):195-203.
liberto rr. treatment of menopausal hot flashes with 5-hydroxytryptophan. mature. 2010;65(4):383-385.
gardener dm, lynd ld. Sumatriptan contraindications and serotonin syndrome. ann pharmacotera. 1998;32(1):33-38.
kind mh, young man, roman ac. Effects of oral 5-hydroxytryptophan on a standardized planning task: insight into potential dopamine/serotonin interactions in the forebrain. hum psychopharmaceutical. 2013;28(3):270-273.
iovieno n, dalton ed, fava m, mischoulon d. second level natural antidepressants: review and critique. j affects disorder. 2011;130(3):343-357.
jangid p, malik p, singh p, sharma m, gulia ak. Comparative study of the efficacy of i-5-hydroxytryptophan and fluoxetine in patients presenting a first depressive episode. asian j psychiatrist. 2013;6(1):29-34.
joffe rt, sokolov street. Coadministration of fluoxetine and sumatriptan: the Canadian experience. acta psychiatr scand. 1997;95(6):551-552.
Joly P, Lampert A, Thomine E, Lauret P. development of pseudobulous morphea and scleroderma-like disease during therapy with l-5-hydroxytryptophan and carbidopa. j am acad dermatol. 1991;25(2pt 1):332-333.
juhl jh. Primary fibromyalgia syndrome and 5-hydroxy-l-tryptophan: a 90-day open-label study. alternate med rev. 1998;3(5):367-375.
keszthelyi d, troost fj, jonkers dm, et al. Visceral hypersensitivity in irritable bowel syndrome: evidence for the involvement of serotonin metabolism: a preliminary study. motile neurogastroenterol. 2015;27(8):1127-1137.
mason bj, blackburn kh. Possible serotonin syndrome associated with co-administration of tramadol and sertraline. ann pharmacotera. 1997;31(2):175-177.
meyers s. use of neurotransmitter precursors for the treatment of depression. alternate med rev. 2000;5(1):64-71.
perry n.k. Venlafaxine-induced serotonin syndrome with relapse after amitripyline. postgraduate medicine j. 2000;76(894):254-256.
puttini ps, caruso i. Primary fibromyalgia and 5-hydroxy-l-tryptophan: a 90-day open-label study. j int med res. 1992;20:(2)182-189.
reibring l, agren h, hartvig p, et al. uptake and utilization of [beta-11c] 5-hydroxytryptophan (5-htp) in human brain studied by positron emission tomography. beef. of psychiatry. 1992;45(4):215-225.
ribeiro ca. l-5-Hydroxytryptophan in the prophylaxis of chronic tension-type headache: a double-blind, randomized, placebo-controlled study. headache. 2000;40(6):451-456.
shaw k, turner j, del mar c. Are tryptophan and 5-hydroxytryptophan effective treatments for depression? a meta-analysis. aust n z j psychiatry. 2002;36(4):488-491.
sternberg em, van woert mh, young sn, et al. development of scleroderma-like disease during therapy with l-5-hydroxytryptophan and carbidopa. new engineer j med. 1980;303(14):782-787.
teitelbaum j. spectrum of chronic fatigue. rakel d, ed. integrative medicine. 3rd ed. Philadelphia, PA: Elsever Saunders; 2012:47.
toner lc, tsambiras bm, catalano g, catalano mc, cooper ds. Central nervous system side effects associated with zolpidem treatment. neuropharmacol clin. 2000;23(1):54-58.
of prague hm. Management of depression with serotonin precursors. biological psychiatry. 1981;16(3):291-310.
zmilacher k, battegay r, gastpar m. l-5-Hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. neuropsychobiology. 1988;20(1):28-33.
